2026年脑膜炎奈瑟菌鉴定、抗菌药物敏感性试验及分子分型的外部质量评估

ECDCMONITORING External quality assessment foridentification, antimicrobial susceptibilitytesting and molecular typing ofN eisseriam eningitidis, 2026 On behalf of the IBDLabNet surveillance network This report was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated byDr Maria Keramarou, and produced by Dr Samy Taha and Prof. Muhamed-Kheir Taha, Institut Pasteur, Paris,France, on behalf of the IBDLabNet consortium, as part of the implementation of Framework ContractECDC/2025/001. AuthorsSamy Taha, Invasive Bacterial Infections Unit, National Reference Centre for Meningococci and Haemophilus influenzae, Institut Pasteur, Université Paris Cité, Paris, France; Muhamed-Kheir Taha, Invasive Bacterial InfectionsUnit, National Reference Centre for Meningococci and Haemophilus influenzae, Institut Pasteur, Université ParisCité, Paris, France AcknowledgementsThe authors would like to thank the members of the IBDLabNet consortium for their support in the design and implementation of this exercise, and all participating EU/EEA laboratories for their engagement and contribution tothe 2026 external quality assessment. Suggested citation: European Centre for Disease Prevention and Control. External quality assessment foridentification, antimicrobial susceptibility testing and molecular typing ofNeisseria meningitidis , 2026. Stockholm:ECDC; 2026. Stockholm,August2026 ISBN 978-92-9498-914-7doi: 10.2900/7753503Catalogue number TQ-01-26-059-EN-N Contents Table of contents..................................................................................................................................3Figures and tables ................................................................................................................................3Abbreviations .......................................................................................................................................4Executive summary...............................................................................................................................51 Introduction ......................................................................................................................................62 Study design and methods .................................................................................................................73 Results..............................................................................................................................................94 Discussion .........................................................................................................................................95 Conclusions ..................................................................................................................................... 176 Recommendations ........................................................................................................................... 17References......................................................................................................................................... 19Annex 1. Participating laboratories and countries .................................................................................. 19 Figures Figure 1. Performance on meningococcal non-culture samples: pathogen identification for NC1 and NC4 (N.meningitidis expected in both samples) .........................................................................................................10Figure 2. Performance on meningococcal non-culture samples: serogroup reporting for NC1 and NC4 (expected:serogroup B for NC1 and serogroup W for NC4)............................................................................................11Figure 3. Culture-based serogroup performance for meningococcal isolates N1 and N2 (expected: serogroup W forN1 and serogroup Y for N2) .........................................................................................................................12Figure 4. Distribution of reported MIC values for selected antibiotics for meningococcal isolates N1 and N2,displayed on a log2 MIC scale .......................................................................................................................13Figure 5. Uptake of whole-genome sequencing for meningococcal isolates N1 and N2 (N1: n=25; N2: n=25) ......14Figure 6. Completeness of reported WGS outputs among WGS-positive submissions for meningococcal isolates ...14 Tables Table 1. Overview of aggregated EU/EEA results for the meningococcal component of the EQA ...........................9Table 1A. EU/EEA participating laboratories....................................................................................................20Table A3.1. Pathogen calls for NC1................................................................................................................22Table A3.2. Serogroup calls for NC1.........................